Use of chloroquine in viral diseases

The Lancet Infectious Diseases

Volumn 11, Issue 9, 2011, Pages 653-654

  Savarino, Andrea ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; CHLOROQUINE; GLYCOPROTEIN P; HYDROXYCHLOROQUINE; KI 67 ANTIGEN; MULTIDRUG RESISTANCE PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CD8+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); CORONAVIRUS INFECTION; DISEASE COURSE; DRUG ACCUMULATION; DRUG EFFICACY; DRUG INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOPATHOLOGY; IN VITRO STUDY; IN VIVO CULTURE; INFLUENZA; INFLUENZA VIRUS A; LETTER; LYMPHOID TISSUE; MEMORY T LYMPHOCYTE; PANDEMIC INFLUENZA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RNA VIRUS INFECTION; SEVERE ACUTE RESPIRATORY SYNDROME; VIRUS INFECTION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CHLOROQUINE; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA, HUMAN; MALE; RNA, VIRAL;

EID: 80051806009     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70092-5     Document Type: Letter

References (12)

1. Paton NI, Lee L, Xu Y, et al. Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. Lancet Infect Dis 2011, published online May 6. 10.1016/S1473-3099(11)70065-2.
2. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R Effects of chloroquine on viral infections: an old drug against today's diseases?. Lancet Infect Dis 2003, 3:722-727.
3. Keyaerts E, Li S, Vijgen L, et al. Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother 2009, 53:3416-3421.
4. Sperber K, Louie M, Kraus T, et al. Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Clin Ther 1995, 17:622-636.
5. Sperber K, Chiang G, Chen H, et al. Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1. Clin Ther 1997, 19:913-923.
6. Murray SM, Down CM, Boulware DR, et al. Reduction of immune activation with chloroquine therapy during chronic HIV infection. J Virol 2010, 84:12082-12086.
7. Di Trani L, Savarino A, Campitelli L, et al. Different pH requirements are associated with divergent inhibitory effects of chloroquine on human and avian influenza A viruses. Virol J 2007, 4:39.
8. Vezmar M, Georges E Reversal of MRP-mediated doxorubicin resistance with quinoline-based drugs. Biochem Pharmacol 2000, 59:1245-1252.
9. Saladino R, Barontini M, Crucianelli M, Nencioni L, Sgarbanti R, Palamara AT Current advances in anti-influenza therapy. Curr Med Chem 2010, 17:2101-2140.
10. Savarino A, Bottarel F, Malavasi F, Dianzani U Role of CD38 in HIV-1 infection: an epiphenomenon of T-cell activation or an active player in virus/host interactions?. AIDS 2000, 14:1079-1089.
11. Chomont N, DaFonseca S, Vandergeeten C, Ancuta P, Sékaly RP Maintenance of CD4+ T-cell memory and HIV persistence: keeping memory, keeping HIV. Curr Opin HIV AIDS 2011, 6:30-36.
12. Aguirre-Cruz L, Torres KJ, Jung-Cook H, et al. Preferential concentration of hydroxychloroquine in adenoid tissue of HIV-infected subjects. AIDS Res Hum Retroviruses 2010, 26:339-342.